Dr. Wolfgang Kaschnitz
Claim this profileMedizinische Universität Graz
Studies Neonatal Hyperkinesia
Studies Attention-Deficit/Hyperactivity Disorder (ADHD)
1 reported clinical trial
3 drugs studied
More about Wolfgang Kaschnitz
Clinical Trial Related5 years of experience running clinical trials · Led 1 trial as a Principal Investigator · 0 Active Clinical TrialsTreatments Wolfgang Kaschnitz has experience with
- Atomoxetine Hydrochloride
- Guanfacine Hydrochloride (TAK-503)
- Placebo
Breakdown of trials Wolfgang Kaschnitz has run
Neonatal Hyperkinesia
Attention-Deficit/Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder (ADHD)
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Wolfgang Kaschnitz specialize in?
Wolfgang Kaschnitz focuses on Neonatal Hyperkinesia and Attention-Deficit/Hyperactivity Disorder (ADHD). In particular, much of their work with Neonatal Hyperkinesia has involved treating patients, or patients who are undergoing treatment.
Is Wolfgang Kaschnitz currently recruiting for clinical trials?
No, Wolfgang Kaschnitz is not currently recruiting for any clinical trials. This may change in the future, so check back later.
Are there any treatments that Wolfgang Kaschnitz has studied deeply?
Yes, Wolfgang Kaschnitz has studied treatments such as Atomoxetine hydrochloride, Guanfacine hydrochloride (TAK-503), Placebo.
What is the best way to schedule an appointment with Wolfgang Kaschnitz?
Apply for one of the trials that Wolfgang Kaschnitz is conducting.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.